ClinicalTrials.gg
RecruitingNCT07570745PARITYUpdated May 6, 2026

Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

A Phase 2 interventional study of Low-dose ATG + PTCy + Ivarmacitinib in Graft-Versus-Host Disease(GVHD) and Bone Marrow Transplantation, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.

Planned enrollment
29th of 72
82 · median 53
Started
2026
with 6 others
Phase 2
18 of 81
8 open now
Primary completion
2028-05
later than 36 of 42 live
Registered
72nd of 81
by date
Lead sponsor
3 of 81
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 81 studies in Graft vs Host Disease with a site in China, this one is the 29th largest by planned enrollment of the 72 interventional ones that give a count, is one of 7 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 36 of the 42 other live ones, and was the 72nd registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Graft vs Host Disease with a site in China, or all of them as a file.
02

Study summary

Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly affecting survival and quality of life. Acute GVHD (aGVHD) typically occurs within 100 days post-transplant, commonly involving skin, gastrointestinal tract, and liver. Chronic GVHD (cGVHD) can appear months to years later.

Despite prophylaxis with calcineurin inhibitors (e.g., cyclosporine or tacrolimus), methotrexate, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy), patients receiving haploidentical transplantation from parous female donors remain at high risk for moderate-to-severe aGVHD.

JAK1-dependent cytokine signaling (IL-6, IFN-γ) is central to GVHD pathogenesis. Selective JAK1 inhibition may attenuate T cell-mediated inflammation while preserving hematopoiesis. Ivarmacitinib (SHR0302) is a highly selective oral JAK1 inhibitor, showing favorable safety and preliminary efficacy in autoimmune and GVHD settings, making it a candidate for early GVHD prophylaxis.

Read the detailed description

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative approach for various hematologic malignancies, marrow failure syndromes, and selected genetic disorders. Despite advances in donor selection, including unrelated, haploidentical, and peripheral blood stem cell (PBSC) sources, graft-versus-host disease (GVHD) continues to be the most common and clinically significant complication, adversely affecting both short- and long-term outcomes. Acute GVHD (aGVHD) typically occurs within the first 100 days post-transplant, primarily involving the skin, gastrointestinal tract, and liver, whereas chronic GVHD (cGVHD) may develop months to years later, often affecting multiple organs. Over the past decades, GVHD prophylaxis has evolved from calcineurin inhibitors (cyclosporine, tacrolimus) combined with methotrexate or mycophenolate mofetil to more targeted strategies. In haploidentical transplantation, post-transplant cyclophosphamide (PTCy) has markedly reduced the incidence of both acute and chronic GVHD. However, moderate-to-severe GVHD still occurs in a subset of recipients, highlighting the need for enhanced prophylactic strategies. Low-dose anti-thymocyte globulin (ATG) combined with PTCy has emerged as a promising regimen, with systematic reviews demonstrating significant reductions in grade II-IV aGVHD and cGVHD without increasing relapse risk, thereby improving GVHD-free survival.

Notably, recipients of haploidentical transplants from parous female donors constitute a high-risk population. Prior studies indicate that such recipients exhibit substantially elevated rates of grade II-IV aGVHD and moderate-to-severe cGVHD compared with recipients from nulliparous female or male donors. For instance, retrospective analyses reported grade III-IV aGVHD incidence of 55.3% and extensive cGVHD of 64.3% in recipients from parous female donors, significantly higher than in recipients from male donors, emphasizing the need for additional prophylactic interventions in this group.

Mechanistically, the JAK-STAT signaling pathway plays a central role in GVHD pathogenesis. Alloreactive donor T cells release proinflammatory cytokines such as IFN-γ, IL-6, and TNF-α, leading to tissue injury. JAK1 mediates critical signaling for IL-6 and IFN-γ, suggesting that selective JAK1 inhibition may attenuate pathogenic T cell responses while preserving hematopoiesis. JAK inhibitors such as ruxolitinib and baricitinib have demonstrated efficacy in steroid-refractory GVHD, and highly selective JAK1 inhibitors like itacitinib have shown promising results in early-phase studies, reducing both acute and chronic GVHD incidences with minimal myelosuppression.

Ivarmacitinib (SHR0302), a novel, orally bioavailable, highly selective JAK1 inhibitor developed in China, exhibits potent JAK1 blockade with limited JAK2 inhibition, theoretically minimizing hematopoietic toxicity. Preclinical models show SHR0302 prevents and mitigates aGVHD without impairing graft-versus-leukemia effects. Early-phase clinical studies in cGVHD patients indicate favorable safety and high response rates, supporting its potential application for aGVHD prophylaxis.

In summary, combining high-selectivity JAK1 inhibition with the established low-dose ATG/PTCy regimen offers a mechanistically rational strategy to further reduce GVHD risk in high-risk haploidentical PBSC recipients from parous female donors. This approach is expected to lower the incidence of acute GVHD without significantly increasing infection or relapse risk, improve long-term GVHD outcomes, and enhance overall survival and quality of life for these high-risk transplant recipients.

03

Conditions studied

  • Graft-Versus-Host Disease(GVHD)
  • Bone Marrow Transplantation

Browse trials for

Keywords

  • Graft-versus-host disease
  • Haploidentical transplantation
  • Low-dose ATG/PTCy
  • JAK1 inhibitor (Ivarmacitinib / SHR0302)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years, any gender. Recipients must be diagnosed with hematologic , such as acute leukemia, myelodysplastic syndrome, or malignant lymphoma, and are planned to undergo haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT).
  2. The donor must be a haploidentical relative within three degrees of kinship and a parous female (having given birth; number of pregnancies not limited), aged 18-55 years, in good health, and cleared by donor screening.
  3. performance status ≥70. The recipient is expected to tolerate transplant-related toxicity. Major organ functions must meet transplantation requirements: cardiac and pulmonary function essentially normal; liver function: /AST \<2× , total \<1.5× upper limit of normal; renal function: >50 mL/min.
  4. No active infection prior to transplantation (or infection effectively controlled). Chronic infections such as , , or syphilis must be stable under treatment; HBV DNA negative or receiving antiviral therapy is acceptable.
  5. No significant psychiatric disorders; able to understand and voluntarily consent to participate in the study.
  6. The patient has signed the form and agrees to comply with follow-up and related examinations.

Exclusion criteria

Exclusion Criteria:

  1. History of prior hematopoietic stem cell transplantation (including or allogeneic transplant).
  2. Presence of donor-specific antibodies (DSA) with a mean fluorescence intensity (MFI) ≥5000.
  3. History of severe or allergy to JAK inhibitors or the drug.
  4. Prior treatment with JAK1/2 inhibitors.
  5. Uncontrolled comorbidities prior to transplantation, such as uncontrolled hypertension, diabetes complications, or active gastrointestinal ulcer bleeding, which may increase unacceptable risk for trial participation as evaluated by investigators.
  6. Receipt of other investigational drugs within 2 weeks prior to transplantation (excluding standard chemotherapy), or simultaneous participation in other interventional clinical studies, or any other condition deemed by the investigator to make the patient unsuitable for study participation, including poor compliance or inability to complete follow-up (e.g., severe psychiatric disorders preventing cooperation).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Low-dose ATG + PTCy + Ivarmacitinib

    Patients will receive rabbit ATG 2.5 mg/kg on Day -2 and -1 (total 5 mg/kg), post-transplant cyclophosphamide 50 mg/kg on Day +3, cyclosporine/MMF starting Day +4, and Ivarmacitinib 4 mg PO daily from Day -3 to +45, reduced to 2 mg PO daily from Day +46 to +60

    Drug: Low-dose ATG + PTCy + Ivarmacitinib

Interventions

  • DrugLow-dose ATG + PTCy + Ivarmacitinib

    Drug pages: Antilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IvarmacitinibStudies of IvarmacitinibIvarmacitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive rabbit ATG 2.5 mg/kg on Day -2 and -1 (total 5 mg/kg), post-transplant cyclophosphamide 50 mg/kg on Day +3, cyclosporine/MMF starting Day +4, and Ivarmacitinib 4 mg PO daily from Day -3 to +45, reduced to 2 mg PO daily from Day +46 to +60

06

What researchers measure

Primary outcomes

  1. Number of Participants With Grades II-IV Acute GVHD

    Acute graft-versus-host disease (aGVHD) will be assessed according to standard criteria (Glucksberg or MAGIC). The primary measure is the occurrence of grade II-IV aGVHD in any organ (skin, liver, gastrointestinal tract) within 180 days after haploidentical peripheral blood stem cell transplantation. Severity will be graded based on clinical manifestations, laboratory results, and endoscopic or biopsy findings where applicable.

    Time frame: From Day 0 to Day 180 post-transplant

Secondary outcomes

  1. Number of Participants With Graft Failure

    Primary graft failure is defined as failure to achieve sustained neutrophil engraftment (ANC ≥ 0.5 × 10⁹/L for 3 consecutive days) and/or platelet engraftment (Platelet ≥ 20 × 10⁹/L without transfusion for 7 consecutive days) by Day 28 post-transplant. Assessment is based on peripheral blood counts and confirmed by the study team.

    Time frame: Day 28 post-transplant

  2. Number of Participants With Non-Relapse Mortality by Day +180

    NRM is defined as death occurring after allogeneic hematopoietic stem cell transplantation without evidence of relapse of the underlying hematologic malignancy. Causes include transplant-related complications such as acute or chronic GVHD, severe infections, organ toxicity, or graft failure. All deaths will be adjudicated by the study team based on clinical, laboratory, and imaging data.

    Time frame: Up to 180 days post-transplant

Other outcomes

  1. Number of Participants With Chronic Graft-Versus-Host Disease by 1 Year

    The cumulative incidence of chronic GVHD will be measured as the occurrence of chronic GVHD (limited or extensive) diagnosed according to NIH consensus criteria within 1 year after transplantation. cGVHD will be assessed clinically using standardized criteria, including organ involvement and requirement for systemic immunosuppressive therapy.

    Time frame: Up to 1 year post-transplant

  2. Number of Participants With Relapse by 1 Year

    Relapse rate is defined as the proportion of patients who develop recurrence of the underlying hematologic malignancy after achieving initial engraftment. Relapse will be confirmed by bone marrow examination, cytogenetic/molecular criteria, or imaging evidence consistent with disease recurrence. Competing risk analysis will treat non-relapse mortality as a competing event.

    Time frame: Up to 1 year post-transplant

  3. Number of Participants Alive at 1 Year

    Overall survival (OS) is defined as the time from the date of transplantation to death from any cause. Patients alive at the end of the follow-up period will be censored at the last known date alive. OS will be estimated using Kaplan-Meier methods.

    Time frame: Up to 1 year post-transplant

  4. Number of Participants Alive and Disease-Free at 1 Year

    Disease-free survival (DFS) is defined as the time from transplantation to the first occurrence of relapse or death from any cause. Patients without relapse or death at the end of the follow-up period will be censored at last follow-up. DFS will be estimated by Kaplan-Meier analysis.

    Time frame: Up to 1 year post-transplant

  5. Number of Participants With GVHD-Free and Relapse-Free Survival at 1 Year

    GVHD-free/relapse-free survival (GRFS) is a composite endpoint defined as survival without grade III-IV acute GVHD, systemic therapy-requiring chronic GVHD, relapse of underlying disease, or death within 1 year after transplantation. Patients who do not experience any of these events will be censored at last follow-up.

    Time frame: Up to 1 year post-transplant

  6. Number of Participants With Any Adverse Event by Day +180

    All adverse events will be recorded and graded according to CTCAE v5.0. Specific monitoring includes hematologic toxicity, liver and renal function abnormalities, metabolic disturbances, and infections (bacterial, viral, fungal). The frequency, severity, and type of AEs will be summarized throughout the 180-day post-transplant period.

    Time frame: From Day 0 to Day 180 post-transplant

07

Study locations

1 of 1 sites recruiting
  • Shanghai General Hospital Affiliated to Shanghai Jiao Tong University
    Shanghai, Shanghai Municipality 210000, China
    Recruiting
08

References and documents

Publications

  • He Q, Sun X, Niu J, Yang J, Wang Y, Huang C, Zhou K, Tong Y, Cai Y, Dong B, Wan L, Song X, Qiu H. A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease: A Phase I Clinical Trial. Cell Transplant. 2024 Jan-Dec;33:9636897241254678. doi: 10.1177/09636897241254678. PubMed 38798038 ↗
  • Sun X, He Q, Yang J, Wang A, Zhang F, Qiu H, Zhou K, Wang P, Ding X, Yuan X, Li H, Zhang Y, Song X. Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease. Cell Transplant. 2021 Jan-Dec;30:9636897211033778. doi: 10.1177/09636897211033778. PubMed 34269100 ↗
  • Schroeder MA, Khoury HJ, Jagasia M, Ali H, Schiller GJ, Staser K, Choi J, Gehrs L, Arbushites MC, Yan Y, Langmuir P, Srinivas N, Pratta M, Perales MA, Chen YB, Meyers G, DiPersio JF. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020 Apr 28;4(8):1656-1669. doi: 10.1182/bloodadvances.2019001043. PubMed 32324888 ↗
  • Kim S, Ashami K, Lim S, Staser K, Vij K, Santhanam S, Ritchey J, Peterson S, Gao F, Ciorba MA, Cooper ML, DiPersio JF, Choi J. Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. Leukemia. 2022 Jan;36(1):292-295. doi: 10.1038/s41375-021-01360-9. Epub 2021 Jul 24. No abstract available. PubMed 34304247 ↗
  • Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, Loberiza FR, Porter DL. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Jul;12(7):758-69. doi: 10.1016/j.bbmt.2006.03.015. PubMed 16785065 ↗
  • Yang J, Jia Y, Hu X, Zhou F, Ni X, Wan J, Ding Y, Kang M, Yu X, Jiang C, Wang L, Wan L, Cai Y, Huang C, Qiu H, Ding X, Tong Y, Dong B, Zhou K, Song X. A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy. Blood. 2026 Jun 25;147(26):3168-3178. doi: 10.1182/blood.2025032569. PubMed 41849227 ↗
  • Xu X, Yang J, Cai Y, Li S, Niu J, Zhou K, Jiang Y, Xu X, Shen C, Huang C, Qiu H, Wei D, Kang M, Tong Y, Wei Z, Liu P, Wan L, Song X. Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood. Bone Marrow Transplant. 2021 Mar;56(3):705-708. doi: 10.1038/s41409-020-01047-2. Epub 2020 Sep 1. No abstract available. PubMed 32873913 ↗
  • Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, van den Brink MRM, Hansen JA, Parkman R, Miklos DB, Martin PJ, Paczesny S, Vogelsang G, Pavletic S, Ritz J, Schultz KR, Blazar BR. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3. PubMed 27713092 ↗
  • Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012 May 11;12(6):443-58. doi: 10.1038/nri3212. PubMed 22576252 ↗
  • Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009 May 2;373(9674):1550-61. doi: 10.1016/S0140-6736(09)60237-3. Epub 2009 Mar 11. PubMed 19282026 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2028, 24 months later.

Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's planned 24 months is below that.

Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 6, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07570745
Responsible party
Xianmin Song, MD (PhD, Department Director, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
May 6, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
May 6, 2026

Study contacts

Xianmin Song, PhD
Contact
shongxm@sjtu.edu.cn
+021-63240090
Xianmin Song, PhD
Contact
Xianmin Song, PhD
principal investigator · Shanghai General Hospital Affiliated to Shanghai Jiao Tong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Ivarmacitinib

Start the discussion